Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis

Fumio Matsumoto; Takeo Imai; Akira Saito; Masumi Tomisawa; Yohmei Hiraga; Mitsuhide Ohmichi; Masao Tamura; Kazuki Konishi; Hitoshi Kobayashi; Kotaro Oizumi; Akira Watanabe; Kiyoshi Konno; Hideo Arai; Izumi Hayashi; Koichiro Nakata; Masayuki Noguchi; Naohiko Chonabayashi; Tatsuo Nakatani; Hiroyuki Kobayashi; Hiroaki Takeda; Hiroshi Oshitani; Junzaburo Kabe; Koichiro Kudo; Shigeki Odagiri; Kaneo Suzuki; Shigeo Takizawa; Masaaki Arakawa; Koichi Wada; Masanaga Takato; Shigeyuki Hoshino; Hajimu Takeda; Osamu Sekine; Yasutoshi Suzuki; Kaoru Oyama; Fumio Miki; Rinzo Soejima; Niro Okimoto; Toshiharu Matsushima; Makoto Kimura; Kohei Hara; Yasumasa Dotsu; Hironobu Koga; Shigeru Kohno; Masahiro Yatsugi; Kazuto Hiratani; Kenji Kawano; Takeshi Ishizaki; Keizo Matsumoto; Hirofumi Tanaka; Masaru Nasu; Yoichiro Goto; Jun Goto; Hideaki Shigeno; Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Nobuya Ogawa

doi:10.11250/chemotherapy1953.38.Supplement1_198

Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis

Fumio Matsumoto, Takeo Imai, Akira Saito, Masumi Tomisawa, Yohmei Hiraga, Mitsuhide Ohmichi, Masao Tamura, Kazuki Konishi, Hitoshi Kobayashi, Kotaro Oizumi, Akira Watanabe, Kiyoshi Konno, Hideo Arai, Izumi Hayashi, Koichiro Nakata, Masayuki Noguchi, Naohiko Chonabayashi, Tatsuo Nakatani, Hiroyuki Kobayashi, Hiroaki TakedaHiroshi Oshitani, Junzaburo Kabe, Koichiro Kudo, Shigeki Odagiri, Kaneo Suzuki, Shigeo Takizawa, Masaaki Arakawa, Koichi Wada, Masanaga Takato, Shigeyuki Hoshino, Hajimu Takeda, Osamu Sekine, Yasutoshi Suzuki, Kaoru Oyama, Fumio Miki, Rinzo Soejima, Niro Okimoto, Toshiharu Matsushima, Makoto Kimura, Kohei Hara, Yasumasa Dotsu, Hironobu Koga, Shigeru Kohno, Masahiro Yatsugi, Kazuto Hiratani, Kenji Kawano, Takeshi Ishizaki, Keizo Matsumoto, Hirofumi Tanaka, Masaru Nasu, Yoichiro Goto, Jun Goto, Hideaki Shigeno, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Nobuya Ogawa

Research output: Contribution to journal › Article › peer-review

Abstract

We performed a dose-finding study on cefetamet pivoxil (CEMT-PI), a new oral cephem, in the treatment of acute exacerbation of chronic bronchitis, by a multicenter well-controlled comparative study. CEMT-PI was orally administered at 500 mg b. i. d., 750mg t. i. d. or 1,000mg b. i. d. The clinical efficacy rate assessed by committee was 61.8% (21/34) in the 500mg group, 67.6% (23/34) in the 750mg group and 72.7% (24/33) in the 1,000mg group. There were no significant differences among the three groups. The bacteriological eradication rate was 81.3%(13/16) in the 500mg group, 78.6% (11/14) in the 750mg group and 66.7% (8/12) in the 1,000mg group. There were no significant differences among the three groups. Except for the cases infected with Staphylococcus aureus and Pseudomonas aeruginosa, bacteriological eradication was 11/13 in the 500mg group, 10/12 in the 750mg group and, 7/8 in the 1, 000mg group. There were no significant differences among the three groups. The incidence of side effects was 11.1% (4/36) in the 500mg group, 2.8%(1/36) in the 750mg group and 2.7% (1/37) in the 1, 000mg group. There were no significant differences among the three groups. We conclude from our results that 1, 000mg b. i. d. is the optimal dose of CEMT-PI in the treatment of acute exacerbation of chronic bronchitis.

Original language	English
Pages (from-to)	198-209
Number of pages	12
Journal	Chemotherapy
Volume	38
DOIs	https://doi.org/10.11250/chemotherapy1953.38.Supplement1_198
Publication status	Published - 1990
Externally published	Yes

Keywords

CEMT-PI
Cefetamet pivoxil

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.38.Supplement1_198

Cite this

Matsumoto, F., Imai, T., Saito, A., Tomisawa, M., Hiraga, Y., Ohmichi, M., Tamura, M., Konishi, K., Kobayashi, H., Oizumi, K., Watanabe, A., Konno, K., Arai, H., Hayashi, I., Nakata, K., Noguchi, M., Chonabayashi, N., Nakatani, T., Kobayashi, H., ... Ogawa, N. (1990). Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis. Chemotherapy, 38, 198-209. https://doi.org/10.11250/chemotherapy1953.38.Supplement1_198

Matsumoto, F, Imai, T, Saito, A, Tomisawa, M, Hiraga, Y, Ohmichi, M, Tamura, M, Konishi, K, Kobayashi, H, Oizumi, K, Watanabe, A, Konno, K, Arai, H, Hayashi, I, Nakata, K, Noguchi, M, Chonabayashi, N, Nakatani, T, Kobayashi, H, Takeda, H, Oshitani, H, Kabe, J, Kudo, K, Odagiri, S, Suzuki, K, Takizawa, S, Arakawa, M, Wada, K, Takato, M, Hoshino, S, Takeda, H, Sekine, O, Suzuki, Y, Oyama, K, Miki, F, Soejima, R, Okimoto, N, Matsushima, T, Kimura, M, Hara, K, Dotsu, Y, Koga, H, Kohno, S, Yatsugi, M, Hiratani, K, Kawano, K, Ishizaki, T, Matsumoto, K, Tanaka, H, Nasu, M, Goto, Y, Goto, J, Shigeno, H, Saito, A, Shigeno, Y, Irabu, Y & Ogawa, N 1990, 'Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis', Chemotherapy, vol. 38, pp. 198-209. https://doi.org/10.11250/chemotherapy1953.38.Supplement1_198

@article{4d074831751444359d50be85b3a7f3ff,

title = "Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis",

abstract = "We performed a dose-finding study on cefetamet pivoxil (CEMT-PI), a new oral cephem, in the treatment of acute exacerbation of chronic bronchitis, by a multicenter well-controlled comparative study. CEMT-PI was orally administered at 500 mg b. i. d., 750mg t. i. d. or 1,000mg b. i. d. The clinical efficacy rate assessed by committee was 61.8% (21/34) in the 500mg group, 67.6% (23/34) in the 750mg group and 72.7% (24/33) in the 1,000mg group. There were no significant differences among the three groups. The bacteriological eradication rate was 81.3%(13/16) in the 500mg group, 78.6% (11/14) in the 750mg group and 66.7% (8/12) in the 1,000mg group. There were no significant differences among the three groups. Except for the cases infected with Staphylococcus aureus and Pseudomonas aeruginosa, bacteriological eradication was 11/13 in the 500mg group, 10/12 in the 750mg group and, 7/8 in the 1, 000mg group. There were no significant differences among the three groups. The incidence of side effects was 11.1% (4/36) in the 500mg group, 2.8%(1/36) in the 750mg group and 2.7% (1/37) in the 1, 000mg group. There were no significant differences among the three groups. We conclude from our results that 1, 000mg b. i. d. is the optimal dose of CEMT-PI in the treatment of acute exacerbation of chronic bronchitis.",

keywords = "CEMT-PI, Cefetamet pivoxil",

author = "Fumio Matsumoto and Takeo Imai and Akira Saito and Masumi Tomisawa and Yohmei Hiraga and Mitsuhide Ohmichi and Masao Tamura and Kazuki Konishi and Hitoshi Kobayashi and Kotaro Oizumi and Akira Watanabe and Kiyoshi Konno and Hideo Arai and Izumi Hayashi and Koichiro Nakata and Masayuki Noguchi and Naohiko Chonabayashi and Tatsuo Nakatani and Hiroyuki Kobayashi and Hiroaki Takeda and Hiroshi Oshitani and Junzaburo Kabe and Koichiro Kudo and Shigeki Odagiri and Kaneo Suzuki and Shigeo Takizawa and Masaaki Arakawa and Koichi Wada and Masanaga Takato and Shigeyuki Hoshino and Hajimu Takeda and Osamu Sekine and Yasutoshi Suzuki and Kaoru Oyama and Fumio Miki and Rinzo Soejima and Niro Okimoto and Toshiharu Matsushima and Makoto Kimura and Kohei Hara and Yasumasa Dotsu and Hironobu Koga and Shigeru Kohno and Masahiro Yatsugi and Kazuto Hiratani and Kenji Kawano and Takeshi Ishizaki and Keizo Matsumoto and Hirofumi Tanaka and Masaru Nasu and Yoichiro Goto and Jun Goto and Hideaki Shigeno and Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Nobuya Ogawa",

year = "1990",

doi = "10.11250/chemotherapy1953.38.Supplement1_198",

language = "English",

volume = "38",

pages = "198--209",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

}

TY - JOUR

T1 - Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Saito, Akira

AU - Tomisawa, Masumi

AU - Hiraga, Yohmei

AU - Ohmichi, Mitsuhide

AU - Tamura, Masao

AU - Konishi, Kazuki

AU - Kobayashi, Hitoshi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Konno, Kiyoshi

AU - Arai, Hideo

AU - Hayashi, Izumi

AU - Nakata, Koichiro

AU - Noguchi, Masayuki

AU - Chonabayashi, Naohiko

AU - Nakatani, Tatsuo

AU - Kobayashi, Hiroyuki

AU - Takeda, Hiroaki

AU - Oshitani, Hiroshi

AU - Kabe, Junzaburo

AU - Kudo, Koichiro

AU - Odagiri, Shigeki

AU - Suzuki, Kaneo

AU - Takizawa, Shigeo

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Takato, Masanaga

AU - Hoshino, Shigeyuki

AU - Takeda, Hajimu

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Oyama, Kaoru

AU - Miki, Fumio

AU - Soejima, Rinzo

AU - Okimoto, Niro

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Hara, Kohei

AU - Dotsu, Yasumasa

AU - Koga, Hironobu

AU - Kohno, Shigeru

AU - Yatsugi, Masahiro

AU - Hiratani, Kazuto

AU - Kawano, Kenji

AU - Ishizaki, Takeshi

AU - Matsumoto, Keizo

AU - Tanaka, Hirofumi

AU - Nasu, Masaru

AU - Goto, Yoichiro

AU - Goto, Jun

AU - Shigeno, Hideaki

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Ogawa, Nobuya

PY - 1990

Y1 - 1990

N2 - We performed a dose-finding study on cefetamet pivoxil (CEMT-PI), a new oral cephem, in the treatment of acute exacerbation of chronic bronchitis, by a multicenter well-controlled comparative study. CEMT-PI was orally administered at 500 mg b. i. d., 750mg t. i. d. or 1,000mg b. i. d. The clinical efficacy rate assessed by committee was 61.8% (21/34) in the 500mg group, 67.6% (23/34) in the 750mg group and 72.7% (24/33) in the 1,000mg group. There were no significant differences among the three groups. The bacteriological eradication rate was 81.3%(13/16) in the 500mg group, 78.6% (11/14) in the 750mg group and 66.7% (8/12) in the 1,000mg group. There were no significant differences among the three groups. Except for the cases infected with Staphylococcus aureus and Pseudomonas aeruginosa, bacteriological eradication was 11/13 in the 500mg group, 10/12 in the 750mg group and, 7/8 in the 1, 000mg group. There were no significant differences among the three groups. The incidence of side effects was 11.1% (4/36) in the 500mg group, 2.8%(1/36) in the 750mg group and 2.7% (1/37) in the 1, 000mg group. There were no significant differences among the three groups. We conclude from our results that 1, 000mg b. i. d. is the optimal dose of CEMT-PI in the treatment of acute exacerbation of chronic bronchitis.

AB - We performed a dose-finding study on cefetamet pivoxil (CEMT-PI), a new oral cephem, in the treatment of acute exacerbation of chronic bronchitis, by a multicenter well-controlled comparative study. CEMT-PI was orally administered at 500 mg b. i. d., 750mg t. i. d. or 1,000mg b. i. d. The clinical efficacy rate assessed by committee was 61.8% (21/34) in the 500mg group, 67.6% (23/34) in the 750mg group and 72.7% (24/33) in the 1,000mg group. There were no significant differences among the three groups. The bacteriological eradication rate was 81.3%(13/16) in the 500mg group, 78.6% (11/14) in the 750mg group and 66.7% (8/12) in the 1,000mg group. There were no significant differences among the three groups. Except for the cases infected with Staphylococcus aureus and Pseudomonas aeruginosa, bacteriological eradication was 11/13 in the 500mg group, 10/12 in the 750mg group and, 7/8 in the 1, 000mg group. There were no significant differences among the three groups. The incidence of side effects was 11.1% (4/36) in the 500mg group, 2.8%(1/36) in the 750mg group and 2.7% (1/37) in the 1, 000mg group. There were no significant differences among the three groups. We conclude from our results that 1, 000mg b. i. d. is the optimal dose of CEMT-PI in the treatment of acute exacerbation of chronic bronchitis.

KW - CEMT-PI

KW - Cefetamet pivoxil

UR - http://www.scopus.com/inward/record.url?scp=0025598217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025598217&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.Supplement1_198

DO - 10.11250/chemotherapy1953.38.Supplement1_198

M3 - Article

AN - SCOPUS:0025598217

SN - 0009-3165

VL - 38

SP - 198

EP - 209

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

ER -

Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this